Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Post-transplant KRd a new SoC for MM?
Post-transplant KRd a new SoC for MM?
07 Jul 2022 bởiAudrey Abella

In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).

Post-transplant KRd a new SoC for MM?
07 Jul 2022
Catheter-directed thrombolysis trumps systemic anticoagulation for submassive pulmonary embolism
Catheter-directed thrombolysis trumps systemic anticoagulation for submassive pulmonary embolism
07 Jul 2022
Diabetes status may influence long-term survival in metastatic breast cancer
Diabetes status may influence long-term survival in metastatic breast cancer
06 Jul 2022